ERMES EVALUATION OF RADIOMITIGATIVE EFFICACY AND SAFETY OF BP-C2

ERMES 对 BP-C2 辐射抑制功效和安全性的评估

• 批准号: 10244496
• 负责人: SERGEI PIGAREV
• 金额: $ 196.02万
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-05-01 至 2021-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10244496
• 关键词: Ammonium; Chronic; Complex; Cutaneous; Dose; Evaluation; Family suidae; Gamma Rays; Injury; Lignin; Modeling; Oral; Radiation Injuries; Radiation Syndromes; Regimen; Safety; Strontium-90; Toxic effect; burn model

The company plans to obtain FDA approval for BP-C2, a lignin-derived polyphenolic complex with ammonium molybdate, as a topical and/or oral treatment against injuries associated with cutaneous radiation syndrome.

该公司计划获得 FDA 批准 BP-C2，这是一种木质素衍生的多酚与钼酸铵的复合物，用于局部和/或口服治疗皮肤放射综合征相关损伤。